Cerium oxide nanoparticles for treatment and prevention of Alzheimer's disease, Parkinson's disease, and disorders associated with free radical production and/or mitochondrial dysfunction
Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by Aβ (1-42) , block Aβ (1-42) -induced neuronal death, block Aβ (1-42) -induced [Ca 2+ ] i dysfunction in neurons, block Aβ (1-42) -induced lipid peroxidation, decrease loss of dopaminergic neurotransmission, or reduce mitochondrial dysfunction in a cell. CeONP can also be effective in treating conditions involving toxic exposures to compounds that induce mitochondrial dysfunction, such as rotenone, cyanide, carbon monoxide, polychlorinated biphenyls (PCBs) and other mitochondrial toxins.
1. A method of treating a subject for Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS), said method comprising:
administering a non-agglomerating composition comprising cerium oxide nanoparticles having an average particle diameter size of about 10 nm to about 20 nm in an amount sufficient to provide a therapeutically effective dose of about 10 ng, 50 ng, 100 ng, 500 ng, 1 μg, 5 μg, 10 μg, or 50 μg per kg body mass to a subject having Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
2. The method according to claim 1 , wherein the non-agglomerating composition includes a carrier without any phosphate buffer.
3. A method of treating a subject for a mitochondrial disease or suffering from the effects of a mitochondrial toxin, comprising:
administering a non-agglomerating composition comprising cerium oxide nanoparticles having an average particle diameter size of about 10 nm to about 20 nm in an amount sufficient to provide a therapeutically effective dose of about 10 ng, 50 ng, 100 ng, 500 ng, 1 μg, 5 μg, 10 μg, or 50 μg per kg body mass to a subject having mitochondrial disease or suffering from the effects of a mitochondrial toxin.
4. The method according to claim 3 , wherein the effects of mitochondrial toxins result from exposure of a cell to rotenone, cyanide, carbon monoxide, or polychlorinated biphenyls (PCBs).
5. The method according to claim 4 , wherein the effects of mitochondrial toxins are mitochondrial failure from inhibition of electron transport in the mitochondria.
6. The method of claim 3 , wherein the subject has a mitochondrial disease.